Search

Displaying results 2401 - 2410 of 7502 in total
  1. Drug

    Glycopyrronium

    go.drugbank.com/drugs/DB00986
    ApprovedInvestigationalVet approved

    [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090] … [L33105] Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium].

  2. Drug

    Secobarbital

    go.drugbank.com/drugs/DB00418
    ApprovedVet approved

    Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties.

  3. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    [L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway. … progression on at least one line of endocrine therapy.

  4. Drug

    Oxazepam

    go.drugbank.com/drugs/DB00842
    Approved

    as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism. … Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous

  5. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Latanoprostene bunod is the first prostaglandin analog with one of its metabolites being nitric oxide (NO). … The novelty of this agent subsequently lies in the proposed dual mechanism of action that stems from both its prostaglandin F2-alpha analog latanoprost acid metabolite and its ability to donate NO for

  6. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    With respect to antiviral therapy, 2-deoxyglucose was shown to be effective against herpes simplex virus by affecting the virus' ability to penetrate cells. … The exact mechanisms of action of 2-deoxyglucose is still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor that prevents ATP production and, ultimately

  7. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Cyclopropylmethylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydromorphinone
  8. Drug

    Udenafil

    go.drugbank.com/drugs/DB06267
    Approved

    It is not yet approved for use in the U.S., E.U., or Canada. … Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena.

  9. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (

  10. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    [L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.